

(*N*-Salicylidene-*D,L*-glutamato)(2-methylimidazole)copper(II)

Vratislav Langer,^{a*} Eva Scholtzová,^b Dalma Gyepesová,^b Mária Kohútová^c and Aladár Valent^c

^aDepartment of Environmental Inorganic Chemistry, Chalmers University of Technology, SE-41296 Göteborg, Sweden, ^bDepartment of Inorganic Chemistry, Slovak Academy of Sciences, Dúbravská cesta 9, SK-845 36 Bratislava, Slovak Republic, and ^cDepartment of Chemical Theory of Drugs, Faculty of Pharmacy, Comenius University, SK-832 32 Bratislava, Slovak Republic

Correspondence e-mail: langer@chem.chalmers.se

Key indicators


Single-crystal X-ray study
 $T = 183\text{ K}$
 Mean $\sigma(\text{C}-\text{C}) = 0.009\text{ \AA}$
 R factor = 0.046
 wR factor = 0.108
 Data-to-parameter ratio = 12.4

For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.

The title racemic compound, $[\text{Cu}(\text{C}_{12}\text{H}_{11}\text{NO}_5)(\text{C}_4\text{H}_6\text{N}_2)]$, adopts a square-pyramidal Cu^{II} coordination with the tridentate *N*-salicylidene-glutamate Schiff base dianion and the 2-methylimidazole ligand in the basal plane. The apex of the pyramid is occupied by a carboxylic acid O atom from the neighbouring chelate at a distance of 2.479 (4) Å, leading to infinite one-dimensional chains along the crystallographic *a* axis. Strong $\text{N}-\text{H}\cdots\text{O}$ and $\text{O}-\text{H}\cdots\text{O}$ hydrogen bonds form a helix parallel to the *c* axis. The electronic structure of the title compound has also been investigated by the *B3LYP* method.

Comment

A group of copper(II) complexes containing Schiff bases, derived from salicylaldehyde and various amino acids, has attracted attention on account of their proven antimicrobial and antiradical activities. A series of copper(II) complexes containing the Schiff base derived from salicylaldehyde and *L*-glutamic acid was synthesized and studied. As neutral ligands, water, imidazole and its derivatives were used (Kohútová *et al.*, 2000). From this group of substances, we have already described (1-methylimidazole)(*N*-salicylidene-*rac*-glutamato)copper(II) (Langer *et al.*, 2003) and aqua-(*N*-salicylidene-methyl-ester-*L*-glutamato)copper(II) monohydrate (Langer *et al.*, 2004). The crystal structure and theoretical investigation of the electronic structure of the title compound, (I), are presented here.



The title compound, (I), consists of $\text{Cu}(\textit{N}\text{-salicylidene-}rac\text{-glutamato})(2\text{-methylimidazole})$ units (Fig. 1). Each copper ion displays a slightly distorted square-pyramidal coordination geometry. The base of the pyramid is formed by the phenolic atom O1, carboxylic acid atom O2 and azomethine atom N1 of the Schiff base *N*-salicylidene-glutamate dianion, and atom N2 of the 2-methylimidazole ligand. The apex of the pyramid consists of the weakly bonded $\text{O}3^{\text{iv}}$ atom [symmetry code: (iv) $1 + x, y, z$] of the carboxylic acid group of an adjacent molecule, at a distance of 2.479 (4) Å. The Cu atom is 0.146 (2) Å above the mean plane defined by the base atoms O1, O2, N1 and N2 (r.m.s. deviation is 0.020 Å), in the direction of the apex. The dimensions of the square base (selected geometrical

Received 28 November 2003

Accepted 15 December 2003

Online 24 December 2003




Figure 1
The asymmetric unit of (I). Displacement ellipsoids are drawn at the 50% probability level.




Figure 2
A chain of molecules in the *a*-axis direction, showing the square-pyramidal coordination of Cu^{II} atoms. For symmetry code, see Table 2.

parameters are presented in Table 1) and the apical bond length are comparable with the corresponding values found in other compounds of this structural type, e.g. aqua(*N*-salicylidene-glycinato)copper(II) hemihydrate (Ueki *et al.*, 1967;




Figure 3
A helical arrangement of molecules *via* hydrogen bonds parallel to the *c* axis. For symmetry codes, see Table 2.

Bkouche-Waksman *et al.*, 1988) and polymeric (3,5-dimethylpyridine-*N*)(*N*-salicylidene-glycinato-*O,N,O'*)copper(II) (Warda, 1997). A polymeric chain is formed by the O3—C12—O2—Cu1...O3^{iv} sequence along the crystallographic *a* axis. Polymeric structures are generally achieved when the apical position is occupied by a carboxylic O atom from an adjacent molecule, forming infinite zigzag chains (Warda, 1997; Langer *et al.*, 2004). The chain of molecules with the square-pyramidal coordination of Cu^{II} atoms is depicted in Fig. 2.

The chains are associated through hydrogen bonding (Table 2). There are strong intermolecular N—H...O and O—H...O hydrogen bonds, forming a helix parallel to the *c* axis (Fig. 3). Weaker hydrogen bonds of the C—H...O type stabilize the three-dimensional network.

The synthesis of the title compound gave a racemic mixture of [Cu(*N*-salicylidene-*D,L*-glutamato)(2-methylimidazole)], even though an optically active parent complex [Cu(*N*-salicylidene-*L*-glutamato)(H₂O)₂] was used in the reaction with imidazole (Kohútová *et al.*, 2000); a similar result was found by Sivý *et al.* (1994) for [Cu(salicylidene-*D,L*-glutamato)(pyridine)].

The values of the calculated Mulliken charges and bond overlap populations indicate a symmetrically distributed electron density around the Cu atom (approximately $-0.3 |e|$ for the N atoms and $-0.4 |e|$ for the O atoms) (Table 3). Such

circular Fourier synthesis, while for the methyl group, the starting position was based on a threefold averaged circular Fourier synthesis. The quantum chemical calculations of the electronic structure of the title compound were performed using *GAUSSIAN98* (Frisch *et al.*, 1998); the *B3LYP/SVP* method and basis set (*SVP* denotes split valence + polarization) (Becke, 1993) were used. The geometry derived from the X-ray structural analysis was used. The calculations were performed for a doublet as the most stable multiplet state; the title compound is an open-shell system, so the unrestricted formalism was used.

Data collection: *SMART* (Siemens, 1995); cell refinement: *SAINT* (Siemens, 1995); data reduction: *SAINT*; program(s) used to solve structure: *SHELXTL* (Bruker, 2001); program(s) used to refine structure: *SHELXTL*; molecular graphics: *DIAMOND* (Brandenburg, 2000); software used to prepare material for publication: *SHELXTL*.

Financial support of this work by the Scientific Grant Agency (VEGA, Slovak Academy of Sciences, Bratislava, project No. 2/3104/23) and the Ministry of Education of the Slovak Republic (grant No. 1/7277/20) is gratefully acknowledged.

References

- Becke, A. D. (1993). *Chem. Phys.* **98**, 5648–5652.
- Bkouche-Waksman, I., Barbe, J. M. & Kvik, Å. (1988). *Acta Cryst.* **B44**, 595–601.
- Brandenburg, K. (2000). *DIAMOND*. Version 2.1d. Crystal Impact GbR, Bonn, Germany.
- Bruker (2001). *SHELXTL*. Version 6.10). Bruker AXS Inc., Madison, Wisconsin, USA.
- Flack, H. D. (1983). *Acta Cryst.* **A39**, 876–881.
- Frisch, M. J., Trucks, G. W., Schlegel, H. B., Scuseria, G. E., Robb, M. A., Cheeseman, J. R., Zakrzewski, V. G., Montgomery, J. A. Jr, Stratmann, R. E., Burant, J. C., Dapprich, S., Millam, J. M., Daniels, A. D., Kudin, K. N., Strain, M. C. *et al.* (1998). *GAUSSIAN98*. Revision A. Gaussian Inc., Pittsburgh, PA, USA.
- Kohútová, M., Valent, A., Mišíková, E. & Mlynarčík, D. (2000). *Chem. Pap.* **54**, 87–90.
- Langer, V., Gyepesová, D., Scholtzová, E., Mach, P., Kohútová, M., Valent, A., & Smrčok, L. (2004). *Z. Kristallogr.* In the press.
- Langer, V., Scholtzová E., Gyepesová, D., Kohútová, M. & Valent, A. (2003). *Acta Cryst.* **E59**, m1181–m1183.
- Sheldrick, G. M. (2002). *SADABS*. Version 2.03. University of Göttingen, Germany.
- Siemens (1995). *SMART* and *SAINT*. Siemens Analytical X-ray Instruments Inc., Madison, Wisconsin, USA.
- Sivý, J., Kettman, V., Krátsmár-Šmogrovič, J. & Breza, M. (1994). *Z. Naturforsch. Teil C*, **49**, 571–578.
- Ueki, T., Ashida, T., Sasada, Y. & Kakudo, M. (1967). *Acta Cryst.* **22**, 870–878.
- Warda, S. A. (1997). *Acta Cryst.* **C53**, 1010–1011.